Oncology
Biosimilars/Oncology
Afatinib
Form: Tablet
THERAPEUTIC AREA: Oncology
Enzalutamide
Form: Capsule
THERAPEUTIC AREA: Oncology
Eribulin
Form: IV Solution
THERAPEUTIC AREA: Oncology
Gefitinib
Form: Tablet
THERAPEUTIC AREA: Oncology
Ibrutinib
Form: Capsule
THERAPEUTIC AREA: Oncology
Lenalidomide
Form: Capsule
THERAPEUTIC AREA: Oncology
Lenvatinib
Form: Capsule
THERAPEUTIC AREA: Oncology
Nilotinib
Form: Capsule
THERAPEUTIC AREA: Oncology
Palbociclib
Form: Tablet
THERAPEUTIC AREA: Oncology
Pomalidomide
Form: Capsule
THERAPEUTIC AREA: Oncology
Ruxolitinib
Form: Tablet
THERAPEUTIC AREA: Oncology
Sunitinib
Form: Capsule
THERAPEUTIC AREA: Oncology
Temozolomide
Form: Capsule
THERAPEUTIC AREA: Oncology
GlobalOne Healthcare Holding
In addition to licensing, the organization is committed to expanding market presence and contract manufacturing for operating companies across the Middle East, Africa, and beyond. This can facilitate the distribution of important healthcare products to regions where they may not be readily available, improving access to care and promoting better health outcomes. Through its commercial partners, the organization can also leverage local knowledge and expertise to navigate the complexities of these markets and ensure the successful introduction of new products.
Finally, the organization recognizes the importance of investing in late-stage biotech and health/medtech startups to expand its healthcare portfolio globally. By supporting the development of promising new products and technologies, the organization can contribute to the advancement of healthcare and improve outcomes for patients around the world. These investments can also generate returns for the organization and its partners, helping to fund future innovation and growth. Overall, the organization’s mandate reflects a commitment to driving innovation, improving access to care, and promoting better health outcomes for all.